Aimmune Therapeutics, Inc. announced that Aimmune's Chief Operating Officer Howard Raff will retire from his position on October 31, 2015. Dr. Raff will become a consultant for Aimmune, working on developing future product opportunities for food allergens.
Aimmune Therapeutics, Inc.
Equities
AIMT
US00900T1079
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+8.30% | 115B | |
+12.99% | 107B | |
-13.56% | 22.31B | |
-3.99% | 21.6B | |
-5.79% | 18.23B | |
-39.93% | 17.62B | |
+7.43% | 14.26B | |
+33.45% | 12.37B | |
-28.30% | 8.28B |